Targeting cancer cells with antibody-based therapies | Dr Dan Lloyd | Think Kent

Echoing the tale of the Trojan Horse, National Teaching Fellow, Dr Dan Lloyd, explains how antibodies are being used as vehicles to target toxic molecules and radioisotopes to cancer cells exclusively, therefore resulting in more specific therapies and potentially minimising side effects.

► SEARCH for a course at the University of Kent: http://www.kent.ac.uk/courses/?utm_so…

► Research at Kent: https://www.kent.ac.uk/research/?utm_…

► SUBSCRIBE for weekly Think Kent lectures: http://www.youtube.com/user/Universit…

ABOUT DR DAN LLOYD
Dr Dan Lloyd is a Reader in Pharmacology in the School of Biosciences at the University of Kent. He is Director of Graduate Taught Programmes in the School of Biosciences and is the Programme Director of the MSc Cancer Biology. He was awarded a National Teaching Fellowship by the Higher Education Academy, an award that recognises teaching in the UK, for his work to engage students in the communication of science.

► Find out more about Dr Dan Lloyd: https://www.kent.ac.uk/bio/profiles/s…

Find the University of Kent on social media:
► Facebook: https://www.facebook.com/Universityof…
► Twitter: https://twitter.com/unikent
► Instagram: https://instagram.com/unikentlive/
► LinkedIn: https://www.linkedin.com/company/univ…

Related videos